Adenosine and the Cardiovascular System

Adenosine is an endogenous nucleoside with a short half-life that regulates many physiological functions involving the heart and cardiovascular system. Among the cardioprotective properties of adenosine are its ability to improve cholesterol homeostasis, impact platelet aggregation and inhibit the i...

Full description

Saved in:
Bibliographic Details
Published in:American journal of cardiovascular drugs : drugs, devices, and other interventions devices, and other interventions, 2019-10, Vol.19 (5), p.449-464
Main Authors: Reiss, Allison B., Grossfeld, David, Kasselman, Lora J., Renna, Heather A., Vernice, Nicholas A., Drewes, Wendy, Konig, Justin, Carsons, Steven E., DeLeon, Joshua
Format: Article
Language:English
Subjects:
Adenosine diphosphate
Adenosine triphosphate
Atherosclerosis
Blood platelets
Cardiac arrhythmia
Cardiac stress tests
Cardiology
Cardiovascular disease
Cardiovascular system
Cholesterol
Endothelium
Heart
Hypoxia
Medicine
Medicine & Public Health
Metabolism
Pharmacology/Toxicology
Pharmacotherapy
Physiology
Plasma
Proteins
Review Article
Sinuses
Smooth muscle
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adenosine is an endogenous nucleoside with a short half-life that regulates many physiological functions involving the heart and cardiovascular system. Among the cardioprotective properties of adenosine are its ability to improve cholesterol homeostasis, impact platelet aggregation and inhibit the inflammatory response. Through modulation of forward and reverse cholesterol transport pathways, adenosine can improve cholesterol balance and thereby protect macrophages from lipid overload and foam cell transformation. The function of adenosine is controlled through four G-protein coupled receptors: A 1 , A 2A , A 2B  and A 3 . Of these four, it is the A 2A  receptor that is in a large part responsible for the anti-inflammatory effects of adenosine as well as defense against excess cholesterol accumulation. A 2A receptor agonists are the focus of efforts by the pharmaceutical industry to develop new cardiovascular therapies, and pharmacological actions of the atheroprotective and anti-inflammatory drug methotrexate are mediated via release of adenosine and activation of the A 2A receptor. Also relevant are anti-platelet agents that decrease platelet activation and adhesion and reduce thrombotic occlusion of atherosclerotic arteries by antagonizing adenosine diphosphate-mediated effects on the P2Y12 receptor. The purpose of this review is to discuss the effects of adenosine on cell types found in the arterial wall that are involved in atherosclerosis, to describe use of adenosine and its receptor ligands to limit excess cholesterol accumulation and to explore clinically applied anti-platelet effects. Its impact on electrophysiology and use as a clinical treatment for myocardial preservation during infarct will also be covered. Results of cell culture studies, animal experiments and human clinical trials are presented. Finally, we highlight future directions of research in the application of adenosine as an approach to improving outcomes in persons with cardiovascular disease.
ISSN:1175-3277
1179-187X
DOI:10.1007/s40256-019-00345-5